Can we defeat death?
FT features Shift Bioscience in The Weekend Essay.
Read the article on FT.com (subscription required).
About Shift Bioscience
Shift Bioscience is a biotech company uncovering the biology of cell rejuvenation to develop new therapies for age-driven diseases.
Cell aging is the primary, underlying driver for many of today’s major diseases, but is yet to be truly leveraged as a therapeutic target. Operating at the intersection of machine learning and cell biology, Shift’s narrow-AI approach leverages large-scale, proprietary multiomic datasets to uncover the hidden biology of cell aging and rejuvenation. Through this, the Company has built a robust pipeline of rejuvenation targets, including SB000 – a novel, single-gene target capable of cell rejuvenation across multiple cell types.
Shift Bioscience was founded in 2017 by Dr Daniel Ives, CEO, and Dr Brendan Swain, CSO. The Company is based at the Gurdon Institute, Cambridge thanks to the Frame Shift bio-incubator, an initiative of the Milner Therapeutics Institute, and has additional computational facilities in Toronto, Canada.